Corium (NSDQ:CORI) touted data today from a pilot bioequivalence study, comparing its Corplex Donepezil transdermal patch to oral Aricept as delivery method for the most commonly prescribed treatment for Alzheimer’s disease.
Data from the pilot study demonstrated that Corium’s transdermal patch met the criteria for bioequivalence to oral Aricept, as measured by primary pharmacokinetic endpoints previously established by the FDA.
Get the full story at our sister site, Drug Delivery Business News.
The post Corium touts clinical data for transdermal delivery of Alzheimer’s drug appeared first on MassDevice.